Edgestream Partners L.P. Makes New $1.50 Million Investment in Kodiak Sciences Inc. $KOD

Edgestream Partners L.P. bought a new position in Kodiak Sciences Inc. (NASDAQ:KOD – Free Report) during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 15,809 shares of the company’s stock, valued at approximately $1,499,000.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. KBC Group NV bought a new stake in shares of Kodiak Sciences in the first quarter valued at about $39,000. Sterling Capital Management LLC lifted its position in Kodiak Sciences by 850.0% during the 3rd quarter. Sterling Capital Management LLC now owns 1,311 shares of the company’s stock worth $124,000 after acquiring an additional 1,173 shares during the period. EverSource Wealth Advisors LLC lifted its position in Kodiak Sciences by 94.5% during the 1st quarter. EverSource Wealth Advisors LLC now owns 1,927 shares of the company’s stock worth $73,000 after acquiring an additional 936 shares during the period. Simplicity Wealth LLC purchased a new stake in Kodiak Sciences during the 3rd quarter valued at about $263,000. Finally, Mirae Asset Global Investments Co. Ltd. purchased a new position in shares of Kodiak Sciences in the third quarter worth about $304,000. Institutional investors own 89.06% of the company’s stock.

Insider Buying and Selling at Kodiak Sciences

In other Kodiak Sciences news, Director Bros. Advisors Lp Baker purchased 807,840 shares of the firm’s stock in a transaction dated Monday, September 28th. The shares were purchased at an average cost of $72.57 per share, with a total value of $58,624,948.80. Following the completion of the purchase, the director owned 19,121,134 shares in the company, valued at approximately $1,387,620,694.38. This represents a 4.41% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this link. Insiders purchased a total of 2,188,845 shares of company stock valued at $181,326,862 in the last quarter. Company insiders own 44.40% of the company’s stock.

Kodiak Sciences Stock Performance

Kodiak Sciences stock opened at $97.17 on Friday. The company’s fifty day moving average price is $83.13 and its 200 day moving average price is $47.59. Kodiak Sciences Inc. has a 1 year low of $19.25 and a 1 year high of $112.79. The stock has a market capitalization of $6.35 billion, a P/E ratio of -23.82 and a beta of 2.02.

Kodiak Sciences (NASDAQ:KOD – Get Free Report) last posted its quarterly earnings data on Thursday, November 12th. The company reported ($1.05) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.06) by $0.01. Sell-side analysts predict that Kodiak Sciences Inc. will post -4.05 EPS for the current year.

Analysts Set New Price Targets

Several equities analysts recently weighed in on KOD shares. Lifesci Capital increased their price target on shares of Kodiak Sciences from $85.00 to $145.00 and gave the stock an “outperform” rating in a report on Monday, September 28th. Weiss Ratings lowered Kodiak Sciences from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, October 6th. Wall Street Zen cut Kodiak Sciences from a “hold” rating to a “sell” rating in a report on Sunday. JPMorgan Chase & Co. boosted their price objective on Kodiak Sciences from $124.00 to $128.00 and gave the company an “overweight” rating in a report on Thursday. Finally, HC Wainwright upped their target price on Kodiak Sciences from $96.00 to $126.00 and gave the stock a “buy” rating in a research note on Monday, October 12th. Six equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $117.86.

View Our Latest Stock Report on Kodiak Sciences

Kodiak Sciences Profile

(Free Report)

Kodiak Sciences is a clinical-stage biopharmaceutical company focused on developing treatments for retinal and other eye diseases. The company’s research centers on therapies designed to address conditions involving damage to the retina and vision loss. Kodiak’s technology platform combines therapeutic antibodies with a biopolymer to create antibody biopolymer conjugates, which are designed to provide sustained treatment effects. Its development programs have included KSI-301, an investigational therapy targeting vascular endothelial growth factor (VEGF) for retinal diseases.

Featured Articles

Institutional Ownership by Quarter for Kodiak Sciences (NASDAQ:KOD)

Receive News & Ratings for Kodiak Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kodiak Sciences and related companies with MarketBeat.com's FREE daily email newsletter.